Inflammatory factors mediate vulnerability to a social stress-induced depressive-like phenotype in passive Coping Rats

Biological Psychiatry

Volumn 78, Issue 1, 2015, Pages 38-48

  Wood, Susan K ^a,b   Wood, Christopher S ^b   Lombard, Calliandra M ^b   Lee, Catherine S ^a   Zhang, Xiao Yan ^a   Finnell, Julie E ^b   Valentino, Rita J ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Affective disorders; Coping; Inflammation; Interleukin 1 ; Social defeat; Susceptibility

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; AUTACOID; INTERLEUKIN 1 RECEPTOR; RECOMBINANT PROTEIN;

ANHEDONIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; COPING BEHAVIOR; DEPRESSION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; INFLAMMATION; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SOCIAL STRESS; ADAPTIVE BEHAVIOR; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPLICATION; DORSAL RAPHE NUCLEUS; DRUG EFFECTS; GENETICS; LOCUS CERULEUS; LONG EVANS RAT; MALE; MENTAL STRESS; METABOLISM; PHYSIOLOGY; SOCIAL DOMINANCE; SPRAGUE DAWLEY RAT;

ADAPTATION, PSYCHOLOGICAL; ANHEDONIA; ANIMALS; DEPRESSION; DOMINANCE-SUBORDINATION; DORSAL RAPHE NUCLEUS; GENE EXPRESSION; INFLAMMATION MEDIATORS; LOCUS COERULEUS; MALE; RATS; RATS, LONG-EVANS; RATS, SPRAGUE-DAWLEY; RECEPTORS, INTERLEUKIN-1; RECOMBINANT PROTEINS; STRESS, PSYCHOLOGICAL;

EID: 84942903882     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2014.10.026     Document Type: Article

References (76)

1. Almeida DM (2005): Resilience and vulnerability to daily stressors assessed via diary methods. Curr Dir Psychol Sci 14:64-68.
2. Albus C (2010): Psychological and social factors in coronary heart disease. Ann Med 42:487-494.
3. Bjorkqvist K (2001): Social defeat as a stressor in humans. Physiol Behav 73:435-442.
4. Friedmann E, Thomas SA, Liu F, Morton PG, Chapa D, Gottlieb SS (2006): Relationship of depression, anxiety, and social isolation to chronic heart failure outpatient mortality. Am Heart J 152:940, e941-e948.
5. Campayo A, Gomez-Biel CH, Lobo A (2011): Diabetes and depression. Curr Psychiatry Rep 13:26-30.
6. Fenton WS, Stover ES (2006): Mood disorders: Cardiovascular and diabetes comorbidity. Curr Opin Psychiatry 19:421-427.
7. Folks DG (2004): The interface of psychiatry and irritable bowel syndrome. Curr Psychiatry Rep 6:210-215.
8. Billings AG, Moos RH (1984): Coping, stress, and social resources among adults with unipolar depression. J Pers Soc Psychol 46:877-891.
9. Folkman S, Lazarus RS (1980): An analysis of coping in a middle-aged community sample. J Health Soc Behav 21:219-239.
10. Goodhand J, Rampton D (2008): Psychological stress and coping in IBD. Gut 57:1345-1347.
11. Esler M, Julius S, Zweifler A, Randall O, Harburg E, Gardiner H, De Quattro V (1977): Mild high-renin essential hypertension. Neuro-genic human hypertension? N Engl J Med 296:405-411.
12. Harburg E, Julius S, McGinn NF, McLeod J, Hoobler SW (1964): Personality traits and behavioral patterns associated with systolic blood pressure levels in college males. J Chronic Dis 17:405-414.
13. Julius S (1981): The Psychophysiology of Borderline Hypertension. New York: Raven.
14. Southwick SM, Vythilingam M, Charney DS (2005): The psychobiology of depression and resilience to stress: Implications for prevention and treatment. Annu Rev Clin Psychol 1:255-291.
15. Miczek KA (1979): A new test for aggression in rats without aversive stimulation: Differential effects of d-amphetamine and cocaine. Psy-chopharmacology (Berl) 60:253-259.
16. Wood SK, Walker HE, Valentino RJ, Bhatnagar S (2010): Individual differences in reactivity to social stress predict susceptibility and resilience to a depressive phenotype: Role of corticotropin-releasing factor. Endocrinology 151:1795-1805.
17. Wood SK, Zhang XY, Reyes BA, Lee CS, Van Bockstaele EJ, Valentino RJ (2013): Cellular adaptations of dorsal raphe serotonin neurons associated with the development of active coping in response to social stress. Biol Psychiatry 73:1087-1094.
18. Wood SK, McFadden KV, Grigoriadis D, Bhatnagar S, Valentino RJ (2012): Depressive and cardiovascular disease comorbidity in a rat model of social stress: A putative role for corticotropin-releasing factor. Psychopharmacology (Berl) 222:325-336.
19. Van Oortmerssen GA, Benus I, Dijk DJ (1985): Studies in wild house mice: Genotype-environment interactions for attack latency. Neth J Zool 35:155-169.
20. Kendler KS, Kessler RC, Heath AC, Neale MC, Eaves LJ (1991): Coping: A genetic epidemiological investigation. Psychol Med 21:337-346.
21. Valentino RJ, Van Bockstaele E (2008): Convergent regulation of locus coeruleus activity as an adaptive response to stress. Eur J Pharmacol 583:194-203.
22. Howard O, Carr GV, Hill TE, Valentino RJ, Lucki I (2008): Differential blockade of CRF-evoked behaviors by depletion of norepinephrine and serotonin in rats. Psychopharmacology (Berl) 199:569-582.
23. Hammack SE, Schmid MJ, Lo Presti ML, Der-Avakian A, Pellymounter MA, Foster AC, et al. (2003): Corticotropin releasing hormone type 2 receptors in the dorsal raphe nucleus mediate the behavioral consequences of uncontrollable stress. J Neurosci 23:1019-1025.
24. Roche M, Commons KG, Peoples A, Valentino RJ (2003): Circuitry underlying regulation of the serotonergic system by swim stress. J Neurosci 23:970-977.
25. Cooper MA, Huhman KL (2007): Corticotropin-releasing factor receptors in the dorsal raphe nucleus modulate social behavior in Syrian hamsters. Psychopharmacology (Berl) 194:297-307.
26. Pearson KA, Stephen A, Beck SG, Valentino RJ (2006): Identifying genes in monoamine nuclei that may determine stress vulnerability and depressive behavior in Wistar-Kyoto rats. Neuropsychopharma-cology 31:2449-2461.
27. Paxinos G, Watson C (2007): The rat brain in stereotaxic coordinates, 6th ed. San Diego: Elsevier Academic Press.
28. Whittle IR, Glasby M, Lammie A, Bell H, Ungerstedt U (1998): Neuropathological findings after intracerebral implantation of micro-dialysis catheters. Neuroreport. 9:2821-2825.
29. Nava F, Calapai G, De Sarro A, Caputi AP (1996): Interleukin-1 receptor antagonist does not reverse lipopolysaccharide-induced inhibition of water intake in rat. Eur J Pharmacol 309:223-227.
30. Pugh CR, Nguyen KT, Gonyea JL, Fleshner M, Wakins LR, Maier SF, Rudy JW (1999): Role of interleukin-1 beta in impairment of contextual fear conditioning caused by social isolation. Behav Brain Res 106:109-118.
31. Andrus BM, Blizinsky K, Vedell PT, Dennis K, Shukla PK, Schaffer DJ, et al. (2012): Gene expression patterns in the hippocampus and amygdala of endogenous depression and chronic stress models. Mol Psychiatry 17:49-61.
32. Southwick SM, Krystal JH, Bremner JD, Morgan CA 3rd, Nicolaou AL, Nagy LM, et al. (1997): Noradrenergic and serotonergic function in posttraumatic stress disorder. Arch Gen Psychiatry 54:749-758.
33. Wong ML, Kling MA, Munson PJ, Listwak S, Licinio J, Prolo P, et al. (2000): Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: Relation to hypercortisolism and corticotropin-releasing hormone. Proc Natl Acad Sci USA 97:325-330.
34. Bernard R, Kerman IA, Thompson RC, Jones EG, Bunney WE, Barchas JD, et al. (2011): Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression. Mol Psychiatry 16:634-646.
35. Borsody MK, Weiss JM (2004): The effects of endogenous interleukin-1 bioactivity on locus coeruleus neurons in response to bacterial and viral substances. Brain Res 1007:39-56.
36. Castanon N, Bluthe RM, Dantzer R (2001): Chronic treatment with the atypical antidepressant tianeptine attenuates sickness behavior induced by peripheral but not central lipopolysaccharide and interleukin-1beta in the rat. Psychopharmacology (Berl) 154:50-60.
37. Yirmiya R, Pollak Y, Barak O, Avitsur R, Ovadia H, Bette M, et al. (2001): Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents. Neuro-psychopharmacology 24:531-544.
38. West CH, Ritchie JC, Boss-Williams KA, Weiss JM (2009): Antide-pressant drugs with differing pharmacological actions decrease activity of locus coeruleus neurons. Int J Neuropsychopharmacol 12:627-641.
39. Rasmusson AM, Hauger RL, Morgan CA, Bremner JD, Charney DS, Southwick SM (2000): Low baseline and yohimbine-stimulated plasma neuropeptide Y (NPY) levels in combat-related PTSD. Biol Psychiatry 47:526-539.
40. Cohen H, Liu T, Kozlovsky N, Kaplan Z, Zohar J, Mathe AA (2012): The neuropeptide Y (NPY)-ergic system is associated with behavioral resilience to stress exposure in an animal model of post-traumatic stress disorder. Neuropsychopharmacology 37:350-363.
41. Primeaux SD, Wilson SP, Cusick MC, York DA, Wilson MA (2005): Effects of altered amygdalar neuropeptide Y expression on anxiety-related behaviors. Neuropsychopharmacology 30:1589-1597.
42. Gelfo F, Tirassa P, De Bartolo P, Croce N, Bernardini S, Caltagirone C, et al. (2012): NPY intraperitoneal injections produce antidepressantlike effects and downregulate BDNF in the rat hypothalamus. CNS Neurosci Ther 18:487-492.
43. Redrobe JP, Dumont Y, Fournier A, Quirion R (2002): The neuro-peptide Y (NPY) Y1 receptor subtype mediates NPY-induced anti-depressant-like activity in the mouse forced swimming test. Neuropsychopharmacology 26:615-624.
44. Illes P, Finta EP, Nieber K (1993): Neuropeptide Y potentiates via Y2-receptors the inhibitory effect of noradrenaline in rat locus coeruleus neurones. Naunyn Schmiedebergs Arch Pharmacol 348:546-548.
45. Finta EP, Regenold JT, Illes P (1992): Depression by neuropeptide Y of noradrenergic inhibitory postsynaptic potentials of locus coeruleus neurones. Naunyn Schmiedebergs Arch Pharmacol 346:472-474.
46. Chavkin C (2011): The therapeutic potential of kappa-opioids for treatment of pain and addiction. Neuropsychopharmacology 36:369-370.
47. Carlezon WA Jr, Beguin C, Knoll AT, Cohen BM (2009): Kappa-opioid ligands in the study and treatment of mood disorders. Pharmacol Ther 123:334-343.
48. Rorick-Kehn LM, Witkin JM, Statnick MA, Eberle EL, McKinzie JH, Kahl SD, et al. (2014): LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. Neuropharmacology 77:131-144.
49. Van Bockstaele EJ, Reyes BA, Valentino RJ (2010): The locus coeruleus: A key nucleus where stress and opioids intersect to mediate vulnerability to opiate abuse. Brain Res 1314:162-174.
50. Carr GV, Bangasser DA, Bethea T, Young M, Valentino RJ, Lucki I (2010): Antidepressant-like effects of kappa-opioid receptor antagonists in Wistar Kyoto rats. Neuropsychopharmacology 35:752-763.
51. Valentino RJ, Commons KG (2005): Peptides that fine-tune the serotonin system. Neuropeptides 39:1-8.
52. Pollier F, Sarre S, Aguerre S, Ebinger G, Mormede P, Michotte Y, Chaouloff F (2000): Serotonin reuptake inhibition by citalopram in rat strains differing for their emotionality. Neuropsychopharmacology 22:64-76.
53. McMahan CJ, Slack JL, Mosley B, Cosman D, Lupton SD, Brunton LL, et al. (1991): A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. EMBO J 10:2821-2832.
54. Hochstrasser T, Ullrich C, Sperner-Unterweger B, Humpel C (2011): Inflammatory stimuli reduce survival of serotonergic neurons and induce neuronal expression of indoleamine 2, 3-dioxygenase in rat dorsal raphe nucleus organotypic brain slices. Neuroscience 184:128-138.
55. Brambilla D, Franciosi S, Opp MR, Imeri L (2007): Interleukin-1 inhibits firing of serotonergic neurons in the dorsal raphe nucleus and enhances GABAergic inhibitory post-synaptic potentials. Eur J Neuro-sci 26:1862-1869.
56. Raison CL, Capuron L, Miller AH (2006): Cytokines sing the blues: Inflammation and the pathogenesis of depression. Trends Immunol 27:24-31.
57. Koo JW, Duman RS (2008): IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc Natl Acad Sci USA 105:751-756.
58. Goshen I, Yirmiya R (2009): Interleukin-1 (IL-1): A central regulator of stress responses. Front Neuroendocrinol 30:30-45.
59. Rothwell NJ, Luheshi GN (2000): Interleukin 1 in the brain: Biology, pathology and therapeutic target. Trends Neurosci 23:618-625.
60. Thomas AJ, Davis S, Morris C, Jackson E, Harrison R, O'Brien JT (2005): Increase in interleukin-1beta in late-life depression. Am J Psychiatry 162:175-177.
61. Owen BM, Eccleston D, Ferrier IN, Young AH (2001): Raised levels of plasma interleukin-1beta in major and postviral depression. Acta Psychiatr Scand 103:226-228.
62. Watkins LR, Hansen MK, Nguyen KT, Lee JE, Maier SF (1999): Dynamic regulation of the proinflammatory cytokine, interleukin-1beta: Molecular biology for non-molecular biologists. Life Sci 65:449-481.
63. Dinarello CA (1996): Biologic basis for interleukin-1 in disease. Blood 87:2095-2147.
64. Frommberger UH, Bauer J, Haselbauer P, Fraulin A, Riemann D, Berger M (1997): Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: Comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci 247:228-233.
65. Fagundes CP, Glaser R, Hwang BS, Malarkey WB, Kiecolt-Glaser JK (2013): Depressive symptoms enhance stress-induced inflammatory responses. Brain Behav Immun 31:172-176.
66. Pace TW, Mletzko TC, Alagbe O, Musselman DL, Nemeroff CB, Miller AH, Heim CM (2006): Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry 163:1630-1633.
67. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al. (2013): A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: The role of baseline inflammatory biomarkers. JAMA Psychiatry 70:31-41.
68. Oppenheim JJ, Zachariae CO, Mukaida N, Matsushima K (1991): Properties of the novel proinflammatory supergene "intercrine" cytokine family. Annu Rev Immunol 9:617-648.
69. Villiger PM, Terkeltaub R, Lotz M (1992): Production of monocyte chemoattractant protein-1 by inflamed synovial tissue and cultured synoviocytes. J Immunol 149:722-727.
70. Sutcigil L, Oktenli C, Musabak U, Bozkurt A, Cansever A, Uzun O, et al. (2007): Pro- and anti-inflammatory cytokine balance in major depression: Effect of sertraline therapy. Clin Dev Immunol 2007:76396.
71. Piletz JE, Halaris A, Iqbal O, Hoppensteadt D, Fareed J, Zhu H, et al. (2009): Pro-inflammatory biomakers in depression: Treatment with venlafaxine. World J Biol Psychiatry 10:313-323.
72. Davison GC, Williams ME, Nezami E, Bice TL, De Quattro VL (1991): Relaxation, reduction in angry articulated thoughts, and improvements in borderline hypertension and heart rate. J Behav Med 14:453-468.
73. Shapiro D, Hui KK, Oakley ME, Pasic J, Jamner LD (1997): Reduction in drug requirements for hypertension by means of a cognitive-behavioral intervention. Am J Hypertens 10:9-17.
74. Gloaguen V, Cottraux J, Cucherat M, Blackburn IM (1998): A meta-analysis of the effects of cognitive therapy in depressed patients. J Affect Disord 49:59-72.
75. Holroyd KA, O'Donnell FJ, Stensland M, Lipchik GL, Cordingley GE, Carlson BW (2001): Management of chronic tension-type headache with tricyclic antidepressant medication, stress management therapy, and their combination: A randomized controlled trial. JAMA 285:2208-2215.
76. Henry JP, Liu YY, Nadra WE, Qian CG, Mormede P, Lemaire V, et al. (1993): Psychosocial stress can induce chronic hypertension in normotensive strains of rats. Hypertension 21:714-723.